This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection

This study has been completed.
Information provided by (Responsible Party):
AGUNCO Obstetrics and Gynecology Centre Identifier:
First received: April 2, 2012
Last updated: April 18, 2012
Last verified: June 2011

Human papillomavirus (HPV) infection is a worldwide problem strictly linked to the development of cervical cancer. Persistence of the infection is one of the main factors responsible for the invasive progression and women diagnosed with intraepithelial squamous lesions are referred for further assessment and surgical treatments which are prone to complications. Despite this, there are several reports on the spontaneous regression of the infection.

In this study the investigators will evaluate the effectiveness of a long term polyhexamethylene biguanide (PHMB)-based local treatment in improve the viral clearance reducing the time exposure to the infection and avoiding the complications associated with the invasive treatments currently available.

Women diagnosed with HPV infection were randomly assigned to receive six months of treatment with a PHMB-based gynaecological solution (Monogin®) or to remain untreated for the same period of time.

The administration of Monogin® has been performed every three days for fifteen days and then every fifteen days for the subsequent six months.

Condition Intervention Phase
HPV Infection Device: Monogin Phase 4

Study Type: Interventional

Further study details as provided by AGUNCO Obstetrics and Gynecology Centre:

Primary Outcome Measures:
  • Number of patients with no HPV infection

Arms Assigned Interventions
Experimental: Monogin Device: Monogin
Gynaecological solution with polyhexamethylene biguanide, pH 4.0
No Intervention: No intervention


Ages Eligible for Study:   30 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • pathologic Pap smear
  • positive "high risk" HPV DNA test
  • positive colposcopy examination

Exclusion Criteria:

  • patients who had undergone wart therapy in the previous six months
  • pregnancy
  • invasive disease
  • immunosuppression
  • previous HPV vaccination
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01571141

Consultorio Familiare Terme Vigliatore, A.S.P. 5
Messina, Italy
Sponsors and Collaborators
AGUNCO Obstetrics and Gynecology Centre
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AGUNCO Obstetrics and Gynecology Centre Identifier: NCT01571141     History of Changes
Other Study ID Numbers: PHMB_HPV
Study First Received: April 2, 2012
Last Updated: April 18, 2012

Keywords provided by AGUNCO Obstetrics and Gynecology Centre:
polyhexamethylene biguanide
intraepithelial lesions
regression rate

Additional relevant MeSH terms:
Polyhexamethylene biguanide
Anti-Infective Agents processed this record on September 21, 2017